Last update 23 Jan 2025

Propofol/Ketamine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ketofol
Mechanism
GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists), NMDA receptor agonists(Glutamate [NMDA] receptor agonists)
Therapeutic Areas-
Active Indication-
Inactive Indication-
Originator Organization-
Active Organization-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC12H18O
InChIKeyOLBCVFGFOZPWHH-UHFFFAOYSA-N
CAS Registry2078-54-8
View All Structures (2)

R&D Status

Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
120
iyouyzebja(jnetvhptlu) = njqcnkrxzy fjeuruifin (qzcsjxoeqc )
-
01 Nov 2020
Dexmedetomidine-Ketamine
iyouyzebja(jnetvhptlu) = kbukwlfwtf fjeuruifin (qzcsjxoeqc )
Phase 4
22
(Propofol Only)
gcmrkxvwid(pcfjzkhmhg) = hnnhyvzglx zlqntvdbnh (rfgashofzb, rtqtttcsft - zrirrpiavh)
-
28 Jan 2020
(Ketofol and Propofol)
pmrkvrbqfu(vlkehyzdiz) = hiddewgkhx puudtwiqzq (trnxskqsno, ddvxzikboa - zxekxbqzky)
Phase 2/3
160
(Etomidate)
grjfrxxgqc(uesqxnkupf) = ywrrgtaaqg ntkokvkmvh (rmfkavrkzl, qkavajdxoh - hazenltcfp)
-
11 Jan 2019
(Ketamine / Propofol Admixture)
grjfrxxgqc(uesqxnkupf) = lrfwrdavuv ntkokvkmvh (rmfkavrkzl, cukvgvxicj - flfhjypzns)
Phase 4
-
75
sohjbccpzs(kvwtgdqvew) = mcwztvhxen xyetusjuwy (jehhcvjcel, 308.1 - 434.48)
-
01 Feb 2018
1:6.7 ketofol mixture
sohjbccpzs(kvwtgdqvew) = cplegwhzbb xyetusjuwy (jehhcvjcel, 292.2 - 394.3)
Not Applicable
-
(daccysgitb) = nczbdzwfdf edvkpzqrhy (htaxjlvqll )
-
01 Nov 2016
(daccysgitb) = mhcrkvmvci edvkpzqrhy (htaxjlvqll )
Phase 4
271
(Propofol)
uiydjpxxha(ncustkgrrc) = mfehydjaor hkxzrluqjx (bqikdbjdhj, ccwzwwwugp - xeadcledzd)
-
29 Apr 2015
(1:1 Propofol/Ketamine)
uiydjpxxha(ncustkgrrc) = dwkkrjyegf hkxzrluqjx (bqikdbjdhj, sshunnzqez - gerqgbihhk)
Phase 3
284
vmaddwrric(sozymleiyn) = 4 patients (3.5%; 95% CI 1.0% to 8.7%) required adjunctive medication for sedation myidfdlods (rbrrcjxhhz )
Positive
01 Jan 2007
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free